You are here

  • Home
  • Archive
  • Volume 94, Issue 9
  • Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function

Article Text

Article menu
Download PDFPDF
Original article
Acute coronary syndromes
Administration of intracoronary bone marrow mononuclear cells on chronic myocardial infarction improves diastolic function
  1. K Yao1,
  2. R Huang1,2,
  3. J Qian1,
  4. J Cui1,
  5. L Ge1,
  6. Y Li1,
  7. F Zhang1,
  8. H Shi1,
  9. D Huang1,
  10. S Zhang1,
  11. A Sun1,3,
  12. Y Zou1,3,
  13. J Ge1,3
  1. 1
    Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China
  2. 2
    Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, China
  3. 3
    Institutes of Biomedical Sciences, Fudan University, Shanghai, China
  1. Dr Junbo Ge, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China; jbge{at}zs-hospital.sh.cn

Abstract

Background: Regeneration of the myocardium and improved ventricular function have been demonstrated in patients with acute myocardial infarction (MI) treated by intracoronary delivery of autologous bone marrow mononuclear cells (BMC) a few days after successful myocardial reperfusion by percutaneous coronary intervention (PCI); however, the effects of intracoronary cell infusion in chronic MI patients are still unknown.

Aims: To investigate whether intracoronary infusion of BMC into the infarct-related artery in patients with healed MI could lead to improvement in left ventricular (LV) function.

Methods: Among 47 patients with stable ischaemic heart disease due to a previous MI (13 (SD 8) months previously), 24 were randomised to intracoronary infusion of BMC (BMC group) and 23 to a saline infusion (control group) into the target vessel after successful PCI within 12 hours after chest pain occurred. LV systolic and diastolic function, infarct size and myocardial perfusion defect were assessed with the use of echocardiography, magnetic resonance imaging (MRI) or 201Tl single-photon-emission computed tomography (SPECT) at baseline and repeated at the 6-month follow-up examination.

Results: BMC treatment did not result in a significant increase in LV ejection fraction in any of the groups by any of the methods used, and the apparent tendency of an improvement was not statistically different between the two groups. The two groups also did not differ significantly in changes of LV end-diastolic and systolic volume, infarct size or myocardial perfusion. However, there was an overall effect of BMC transfer compared with the control group with respect to early/late (E/A) (p<0.001), early diastolic velocity/late diastolic (Aa) velocity (Ea/Aa) ratio (p = 0.002) and isovolumetric relaxation time (p = 0.038) after 6 months, as evaluated by tissue Doppler echocardiography. We noted no complications associated with BMS transfer.

Conclusion: Intracoronary transfer of autologous BMC in patients with healed MI did not lead to significant improvement of cardiac systolic function, infarct size or myocardial perfusion, but did lead to improvement in diastolic function.

https://doi.org/10.1136/hrt.2007.137919

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • (An additional table is published online only at http://heart.bmj.com/content/vol94/issue9

    • Funding: This work was supported by the Shanghai Scientific Research Fund (06DJ14001), Program for Shanghai Outstanding Medical Academic Leader (LJ06008) and National Key program (2006CB943704).

    • Competing interests: None.